Загрузка...
The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management of chronic myeloid leukemia (CML). Imatinib produces acceptable responses in ~ 60% of patients; with ~20% discontinuing therapy due to intolerance and ~20% developing drug resistance. The advent of newer TKIs...
Сохранить в:
| Опубликовано в: : | Cancer J |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4742366/ https://ncbi.nlm.nih.gov/pubmed/26841016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000165 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|